Temporary pulsatile ventricular assist devices and biventricular assist devices.

BACKGROUND: During the past years several systems for mechanical circulatory support have become available. In this study we describe our experience with short-term and mid-term application of the ABIOMED and Thoratec device. METHODS: Since 1990 the ABIOMED BVS and since 1992 the Thoratec VAD have been applied to 75 and 103 patients, respectively, with postcardiotomy heart failure, as a bridge-to-transplant procedure, and with different other indications. RESULTS: In the ABIOMED collective 25 of 50 patients (50%) with postcardiotomy heart failure and 1 of 4 patients with miscellaneous other indications could be discharged from hospital, 7 of 14 bridge-to-transplant patients (50%) underwent transplantation with a posttransplant survival of 86%. In the Thoratec collective 6 of 10 patients (60%) with postcardiotomy heart failure and 4 of 8 patients (50%) with miscellaneous indications could be discharged from hospital, 48 bridge-to-transplant patients (74%) underwent transplantation with a posttransplant survival of 90%. CONCLUSIONS: The results show the versatility of the Thoratec VAD for short-term and mid-term application in patients with postcardiotomy heart failure and as a bridge-to-transplant procedure. The use of the ABIOMED device is not indicated for bridging patients to transplantation. Although in case of postcardiotomy heart failure, Thoratec is also superior to ABIOMED, the high costs of the Thoratec VAD limits its wide acceptance in this patient cohort.     

Effect of circulatory assist devices on stunned myocardium

We studied the effects of mechanical circulatory assist devices on left ventricular oxygen consumption, the integrals of systolic left ventricular wall stress (SSI), and end-systolic elastance (Ees) in 8 sheep after 25 minutes of global ischemia. Extracorporeal membrane oxygenation at 35 mL/kg/min, intraaortic balloon counterpulsation, and an intraaortic double-balloon pump were studied alone or in combination. Left ventricular oxygen consumption, SSI, and Ees were measured before and during mechanical circulatory assistance. Left ventricular oxygen consumption was calculated from transit-time measurements of left main coronary artery blood flow and fiberoptic measurements of coronary sinus blood oxygen saturation. Three pairs of sonomicrometry crystals placed across three orthogonal ventricular axes were used to calculate instantaneous ventricular volumes and pressure-volume loops from which the SSI data were derived. The Ees was measured using a new single-beat aortic occlusive method. Extracorporeal membrane oxygenation alone increased SSI and did not change Ees in postischemic poorly contracting hearts. Intraaortic balloon counterpulsation alone significantly reduced SSI and increased Ees. The combination of extracorporeal membrane oxygenation and either the intraaortic balloon pump or the intraaortic double-balloon pump reduced SSI, increased Ees, and reduced left ventricular oxygen consumption. In postischemic dilated, poorly contracting hearts, the combination of extracorporeal membrane oxygenation and intraaortic balloon counterpulsation has important advantages over extracorporeal membrane oxygenation alone.     

Replacement of paracorporeal ventricular assist devices.

In this communication we describe a technique to change paracorporeal ventricular assist devices after the development of mechanical complications. This procedure is technically simple and in our experience does not require a sternotomy or cardiopulmonary bypass. Paracorporeal ventricular assist devices can be safely changed allowing continued support and survival.     

Nonlinear controller for ventricular assist devices

This paper presents the design of a gain-scheduled proportional integral (PI) feedback controller for ventricular assist devices to maintain physiologically motivated perfusion. The selected control objective is to maintain an average differential pressure deltaP between the left ventricle and the aorta. Computer simulations for different pathological conditions, ranging from the normal heart to left heart asystole, and a wide range of physiological scenarios, ranging from rest to strenuous exercise, were used to validate the performance of the controller and the effectiveness of the selected control objective in ensuring physiologically adequate perfusion under different clinical and cardiac demand conditions.     

Explantation of a mechanical assist device: assessment of myocardial recovery

Reliable predictors of myocardial recovery post-mechanical assist device implantation are not well defined. We report the case of a 29-year-old woman with refractory congestive heart failure due to acute myocarditis of unknown etiology. The patient was supported with a HeartMate (Thoratec Corp., Woburn, MI) left ventricular assist device for 100 days showing improvement in clinical status. Hemodynamic monitoring, dobutamine stress echocardiography, and cardiopulmonary testing were performed to identify myocardial recovery. Improvements in myocardial reserve, hemodynamic parameters, and myocardial oxygen consumption were identified prior to explantation. The patient was successfully explanted. This case confirms that myocardial recovery is feasible with the use of a mechanical assist device. This article describes our current left ventricular assist device weaning protocol.     

Ventricular assist devices and anesthesia

Ventricular assist devices (VADs) have revolutionized long-term care for patients with congestive heart failure. These patients represent about 1% of the adults in the United States, considering that heart failure is a contributing factor in more than 250,000 deaths annually. It has been estimated that about 60,000 patients per year in the United States could benefit from heart transplantation or long-term mechanical support. Because of the short supply of donor hearts for transplant, assist devices have become of great value. At least four assist devices are clinically available, and two other devices are being investigated. Because cardiopulmonary by-pass is required for implantation of these devices, anesthetizing these critically compromised patients requires extensive monitoring, skillful anesthetic management, and expert postoperative care.     

A detailed explantation assessment protocol for patients with left ventricular assist devices with myocardial recovery

Open in a separate window OBJECTIVESLeft ventricular assist device (LVAD) implantation for end-stage heart failure patients has been on the rise, providing a reliable long-term option. For some LVAD patients, longer term LV unloading leads to recovery; hence, the need for evaluating potential myocardial recovery and weaning eligibility has emerged.METHODSAll patients who underwent contemporary LVAD explantation at our institution between 2009 and 2020 were included in the study. Patients in New York Heart Association I, left ventricular ejection fraction >40%, a cardiac index >2.4 l/min and a peak oxygen intake >50% predicted underwent a 4-phase weaning assessment. A minimally invasive approach using a titanium plug was the surgery of choice in the most recent explants. Kaplan–Meier curves were used to estimate the survival at 1 and 5 years.RESULTSTwenty-six patients (17 HeartMate II, 9 HeartWare) underwent LVAD explantation after a median 317 days of support [IQ (212–518)], range 131–1437. Mean age at explant was 35.8 ± 12.7 years and 85% were males. Idiopathic dilated cardiomyopathy was the underlying diagnosis in 70% of cases. Thirteen (48%) patients were on short-term mechanical circulatory support and 60% required intensive care unit admission prior to the LVAD implantation. At 1 year, Kaplan–Meier estimated survival was 88%, whereas at 6 years, it was 77%. The average left ventricular ejection fraction at 1 year post-explant was 44.25% ± 8.44.CONCLUSIONSThe use of a standardized weaning protocol (echocardiographic and invasive) and a minimally invasive LVAD explant technique minimizes periprocedural complications and leads to good long-term device-free survival rates.     

缺血后处理对猪心肌细胞Fas基因蛋白表达及Caspase-3活性的影响

目的探讨缺血后处理对猪心肌细胞Fas基因蛋白表达及Caspase-3活性的影响。方法24只小型约克猪(体重35～40kg)被随机分为4组。组1(ACC组,n=6)：于CPB开始后并行循环45 min,阻断主动脉90 min,开放主动脉后心脏再灌注120 min；组2(pre-con组,n=6)：升主动脉阻断前进行心脏缺血预处理(阻断升主动脉5 min、开放10 min,重复3次),余处理与组1相同；组3(post-con组,n=6)：并行循环45 min,阻断主动脉90 min,开放主动脉后心脏再灌注120 min；再灌注开始进行缺血后处理(阻断升主动脉30 s后开放30 s,重复3次,共3 min)；组4(pre-con +post-con组,n=6)：升主动脉阻断前进行心脏缺血预处理(阻断升主动脉5 min、开放10 min,重复3次),阻断主动脉90 min,开放主动脉心脏再灌注120 min,再灌注开始进行心肌缺血后处理(阻断升主动脉30 s、开放30 s,重复3次共3 min)。在再灌注结束后取左心室全层心肌适量并固定。用原位化学法(TUNEL)观察各组心肌细胞凋亡,流式细胞法检测Fas基因蛋白表达及Caspase-3的活性。在CPB前、缺血90 min、再灌注30、60、120 min采静脉血检测血MDA、SOD水平。结果原位化学法测得心肌细胞凋亡率组2(10．46±0．91)%、组3(9．68±0．59)%和组4(11．35±1．37)%显著低于组1(19．75±1．81)%(P＜0．05)；流式细胞法测得Fas,Caspase-3荧光表达指数(FI),组2(1．24±0．13和1．32±0．13)、组3(1．27±0．07和1．33±0．08)和组4(1．27±0．14和1．31±0．12)显著低于组1(1．74±0．11和1．99±0．12)(P＜0．05)；与组1相比,MDA血浆浓度组2、组3和组4显著低于组1,而SOD浓度却显著高于组1(P＜0．05)。组2、组3和组4上述指标差异无统计学意义(P＞0．05)。结论Fas、Caspase-3表达改变参与了心肌细胞凋亡及缺血再灌注损伤过程；缺血后处理可以明显减少心肌细胞凋亡,抑制缺血再灌注损伤。心肌细胞凋亡的减少与Fas基因蛋白的下调、抑制Caspase-3活性及氧化应激有关；缺血后处理与缺血预处理相比可以同等程度的减少心肌细胞凋亡。本实验未观察到缺血预处理和缺血后处理的叠加作用。     

Patient selection for left ventricular assist devices

The use of mechanical support as a bridge to cardiac transplant has become the standard of care in many cardiac transplant centers. This therapy has been shown to increase survival and improve morbidity in carefully selected patients waiting for heart transplantation. With approximately 30000 patients being listed worldwide for transplant every year and only 3500 transplantations performed annually, alternative strategies need to be developed to minimize morbidity and mortality in this high-risk population. Patient selection remains the primary determinant of success with left ventricular assist device (LVAD) therapy. This article will review both the cardiac and extracardiac considerations needed in the assessment of patient suitability for LVAD support as a bridge to transplantation.     

A case series of patients with left ventricular assist devices and concomitant mechanical heart valves

Mechanical heart valves left in situ at the time of left ventricular assist device (LVAD) implantation are thought to potentially increase the risk of thromboembolism. Recommendations exist to replace dysfunctional mechanical mitral valves and any mechanical aortic valves at the time of LVAD implantation. Due to potential increases in cardiopulmonary bypass time and associated comorbidities with valve replacement, leaving a functional mechanical valve in place at LVAD implantation has been suggested to be a safe option. We retrospectively reviewed all patients with prior mechanical mitral or aortic valves undergoing LVAD implantation at our center between 2012 and 2017. Echocardiograms were read by a single cardiologist to assess for mechanical valve dysfunction. We identified 15 patients. Five patients had major bleeding requiring transfusion. On follow-up, 2 patients had hemorrhagic stroke and 2 had transient ischemic attach/ischemic stroke. In addition, 2 patients had LVAD thrombosis and 2 patients had LVAD driveline malfunction. Mild mechanical valve regurgitation was identified on follow-up echocardiograms of 2 patients. Rate of complications in patients with mechanical valves undergoing LVAD implantation was comparable to that reported for the general LVAD population. Leaving a functional mechanical valve in place at the time of LVAD implantation could be a reasonable alternative to valve replacement. More data are required to further guide patient care in these individuals.     

Bioengineering of liver assist devices

Over 30 000 patients die annually in the United States from liver failure. In fulminant hepatic failure, a clinical syndrome associated with high mortality, orthotopic liver transplantation is the primary therapeutic option for patients not responding to supportive therapy. However, the persistent scarcity of donor organs has limited this therapeutic modality, resulting in a continued increase in the number of patients who die waiting for a donor liver. An extracorporeal bioartificial liver device could provide vital support to a liver failure patient until a donor liver was available or until the patient's own liver regenerated. Although it is unclear which liver-specific functions must be provided by such a device to be effective, a constant challenge has been to obtain stable, well-differentiated, and normally functioning hepatocytes that can be cultured at high cell densities. Many of the devices currently undergoing clinical trials are limited by designs which are prone to substrate limitations, resulting in compromised hepatocyte function. In devices that avoid substrate limitations, hepatocyte functions can be optimized, thereby leading to increased device efficiency. In this overview, the authors describe the critical issues involved in bioartificial liver development and discuss their experiences in hepatocyte culture optimization within the context of a microchannel, flat-plate bioartificial liver device with an internal membrane oxygenator. Received: March 20, 2002 / Accepted: April 15, 2002 Acknowledgment. The authors thank Dr. Harihara Baskaran for the preparation of Figure 2. This work was partially funded by grants from the National Institutes of Health (DK43371) and The Whitaker Foundation. Offprint requests to: M. Toner     

Ventricular assist devices for postcardiotomy cardiogenic shock. A combined registry experience.

Data submitted voluntarily to the combined registry since its inception in 1985 to December 31, 1990, on the use of ventricular assist devices for postcardiotomy cardiogenic shock in 965 patients were analyzed. Approximately 45% of patients were weaned from temporary circulatory assistance and 24.6% reached hospital discharge regardless of the original operation. In 90% of patients who were discharged from the hospital, circulatory support was able to be discontinued by 1 week. Rates of weaning and discharge were statistically different and favored those patients requiring univentricular support only. Results were equal whether nonpulsatile centrifugal or pulsatile pneumatic devices were used for support. Although complications were frequent and multiple during assist pumping, patient variables including age greater than 70 years rather than direct complications caused by circulatory support were likely to affect overall outcome. In patients achieving hospital discharge, 2-year actuarial survival was 82% with 86% of patients being in New York Heart Association functional class I or II. In rare instances of device dependency in 43 patients (4.5%) with no contraindications to transplantation, 32 (74.4%) underwent bridge to cardiac transplant and 20 (62.5%) were discharged. This multi-institutional experience would continue to support the use of ventricular assist devices in postcardiotomy cardiogenic shock.     

Critical anatomic dimensions for intrathoracic circulatory assist devices

The design of totally implantable circulatory support devices must account for the anatomical constraints of the body cavity. To aid development of an implantable electrohydraulic ventricular assist device (EVAD), thoracic anatomical measurements and fit trials were performed. Various dimensions of the thoracic cavity were measured in 19 preserved and fresh cadavers. The mean left ventricle apex to chest wall distance was 2.7 +/- 0.2 cm. The mean sagittal radius of curvature at the fifth rib was 11.1 +/- 0.4 cm, and the transverse radius at the fifth rib was 9.4 +/- 0.3 cm. The mean sternal length was 18.9 +/- 1.2 cm. Using these measurements a model measuring 17.5 x 10.5 x 3.8 cm was designed. This model was placed in the chest of 11 patients undergoing open heart surgery. In one patient there was significant lung compression and in another hypotension suggesting great vessel compression. Finally, 1 of 11 patients had a short sternum and a small thorax, and the device did not fit. In conclusion, thoracic measurements may be used in the design of circulatory support devices. The model fit adequately in 73% of patient trials.     

Infection during circulatory support with ventricular assist devices.

BACKGROUND: This study is a retrospective analysis of infections in patients supported by ventricular assist devices (VADs) as a bridge to cardiac transplantation. METHODS: Infections were assigned to four classes. Class I were patient-related nonblood infections, class II were blood-borne infections, class III were percutaneous site infections, and class IV were infections of intracorporeal VAD components. RESULTS: The cumulative number and incidence of infections were higher during the early VAD experience than in more recent patients (p < 0.05), although the cumulative number and incidence of class II and IV infections were similar in earlier and later patients. There were 28 serious (ie, class II and IV) infections in 9 patients who died, and 35 serious infections in 11 patients who survived until transplantation. Three of 4 patients with class IV infections died. A larger cumulative number of infections (ie, total class I-IV) was associated with more fungal isolates (p < 0.001) and more class II and IV infections (p < 0.02). Positive fungal cultures were obtained in 16 patients, but there were only 3 class III and 1 class IV fungal isolates. CONCLUSIONS: Infection remains an important problem for patients with VADs. Bloodstream infections (class II) can often be controlled by appropriate therapy. However, intracorporeal device infections (class IV) are associated with substantial morbidity and mortality. Optimal implant techniques together with optimal wound care, appropriate use of prophylactic antibiotics, and avoidance of infection in indwelling catheters remain the most practical means for minimizing the risk of VAD infection.     

Perioperative management of ventricular assist devices

OBJECTIVE: To review the perioperative anaesthetic management of ventricular assist devices. DATA SOURCES: Extraction from Pubmed database of french and english articles on the perioperative anaesthetic management of ventricular assist devices for 15 years. DATA SELECTION: The collected articles were reviewed and selected according to their quality and originality. The more recent data were selected. DATA SYNTHESIS: Cardiac transplantation is an effective treatment for patients in end stage cardiac failure, but the average waiting time of 17 months, associated with the lack of organs (357 out of 832 candidates were transplanted in 1996) results in a high number of deaths in patients awaiting transplantation. The appearance in the 1980's, of the first ventricular assist device (VAD) provided a new possibility for the management of patients with end-stage cardiac failure awaiting transplantation ("bridge to transplant"). The perioperative anaesthetic management of these patients is complex. End stage cardiac failure, poorly responsive to pharmacological interventions, results rapidly in secondary organ dysfunctions. VADs produce a rapid improvement in haemodynamic, renal, hepatic and neuro-endocrine functions over a 2 months period, allowing transplantation to take place under optimal conditions. However VADs are not without complications (1 year mortality of 20%), of which the major are: infections (40%), perioperative haemorrhage (30%) and thrombo-embolic sequelae (30%). A best knowledge of pathophysiology of these complications is necessary to an optimal management of patients with ventricular assist devices.